Stay updated on PATHWay Study: Adjuvant Pembrolizumab Clinical Trial

Sign up to get notified when there's something new on the PATHWay Study: Adjuvant Pembrolizumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PATHWay Study: Adjuvant Pembrolizumab Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The record now displays the PATHWay trial’s details, including its completed status, treatment arms and outcomes, eligibility criteria, study locations, and posted results and study documents.
    Difference
    52%
    Check dated 2026-11-08T11:24:06.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.2 to v3.8.0; the study page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T12:17:51.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A site-wide banner announces updates about NIH’s transition from using the term “Artificial Intelligence” to “Super Intelligence.”
    Difference
    1%
    Check dated 2026-10-25T12:37:49.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T11:59:37.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T12:51:14.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The study detail page now shows a 403 Forbidden error, preventing access to the page content. This indicates an access or server issue rather than a content update to the study details.
    Difference
    0.5%
    Check dated 2026-09-27T17:14:31.000Z thumbnail image

Stay in the know with updates to PATHWay Study: Adjuvant Pembrolizumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PATHWay Study: Adjuvant Pembrolizumab Clinical Trial page.